FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Novartis Bioventures Ltd 2. Issuer Name and Ticker or Trading Symbol Galera Therapeutics, Inc. [ GRTX ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
_____ Officer (give title below)    __X__ Other (specify below)
Former 10% Owner
(Last)         (First)         (Middle)
FORUM 1 - 1.32, LICHTSTRASSE 35, CH-4056		 3. Date of Earliest Transaction (MM/DD/YYYY)
6/18/2020
(Street)
BASEL, V8 CH-4056
(City)       (State)       (Zip)
 4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
 6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  6/18/2020    S    900  D $9.04 (1) 3469273  D (2)
 
Common Stock  6/19/2020    S    1001312  D $8.25 (3) 2467961  D (2)
 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  Reflects sales of common stock executed in multiple transactions at prices ranging from $9.00 to $9.37. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
(2)  Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities.
(3)  Reflects sales of common stock executed in multiple transactions at prices ranging from $8.25 to $9.17. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Novartis Bioventures Ltd
FORUM 1 - 1.32, LICHTSTRASSE 35, CH-4056
BASEL, V8 CH-4056


Former 10% Owner
NOVARTIS AG
LICHTSTRASSE 35, CH-4056
BASEL, V8 CH-4056


Former 10% Owner

Signatures
/s/ Bartosz Dzikowski, Secretary of the Board of Novartis Bioventures Ltd 6/22/2020
**Signature of Reporting Person Date
/s/ Beat Steffen, Authorized Signatory on behalf of Novartis Bioventures Ltd 6/22/2020
**Signature of Reporting Person Date
/s/ Bartosz Dzikowski, Authorized Signatory on behalf of Novartis AG 6/22/2020
**Signature of Reporting Person Date
/s/ Beat Steffen, Authorized Signatory on behalf of Novartis AG 6/22/2020
**Signature of Reporting Person Date